- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05091385
Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma
The Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma Treated in Poland. The Real-life Observational Study
This study is aimed at evaluation of the efficacy of mepolizumab 100 mg SC every 4 weeks in patients with severe eosinophilic asthma who have been treated for at least 12 months in several Polish allergy/asthma centres under the same protocol. Target population to be recruited has been set at 130 subjects from at least 6 asthma centers throughout the country. Data on dempgraphics and asthma status will be collected using questionnaires at 3 time-points: pre-MEPO, after 24 weeks of MEPO and after 1 year of MEPO administration (some of the outcomes will be observed every 4 weeks). Primary endpoints will include:
- Asthma exacerbations measured at qualification for the treatment (in the period of previous 52 weeks) and at the 24th and 52nd week of the treatment.
- Oral Corticosteroids use dose (documented at qualification for the treatment and at the 24th and 52nd week of the treatment).
연구 개요
상태
정황
상세 설명
This study is aimed at evaluation of the efficacy of mepolizumab 100 mg SC every 4 weeks in patients with severe eosinophilic asthma who have been treated for at least 12 months in several Polish allergy/asthma centres under the same protocol. Retrospective multicentre observational study will involve 130 patients with severe eosinophilic asthma ( SEA ) who have been treated in six Severe Asthma Treatment Centres ( SATCs) in Poland. In each SATC all data available in the program questionnaires will be transferred to the Study Data Sheet (questionnaire), and will be send to the study coordinator within 5 months from the study beginning The start-up meeting including partners from all centres involved will be organized to discuss the study protocol and to unify data collection The evaluation parameters (exacerbations rate, OCS dose) will be analysed at least at three time points: pre-MEPO, after 24 weeks of MEPO and after 1 year of MEPO administration (some of the outcomes will be observed every 4 weeks, for the details see 'study endpoints' section).
In addition the following parameters which are available in patients' records will be analysed:
- ACQ-5 score (measured at qualification for the treatment and every 4 weeks thereafter)
- AQLQ score (measured at qualification for the treatment and every 4 weeks thereafter)
- Pre-bronchodilator FEV1 (measured at qualification for the treatment and every 4 weeks thereafter)
Research activities will include:
- collecting raw data from the clinical centres (paper version) and constructing a raw dataset (digital version),
- data cleaning, computation of variables,
- statistical analysis typical for pre-post study design (the statistical analysis will be outsourced to the specialized private institute).
Clinical improvements observed at 24 weeks and at 52 weeks of treatment with Mepolizumab will be referred to the following characteristics of patients at baseline:
- demographics,
- presence of comorbidities including the atopic status,
- concomitant pharmacotherapy,
- clinical status,
- eosinophilia. We will control for mepolizumab use regarding dose, treatment duration and dosing frequency as well as for the safety profile based on the AEs reporting in the medical documentation.
Data Source / Data Collection Patients recruited to the study had been treated with mepolizumab between December 2017 and December 2019.All the data planned to be used in the proposed study were systematically collected in the form of the clinical documentation (paper version) and will be transferred in the study centres into the study.
Data Sheets. Collaborating Researchers (Severe Asthma Centres' Leaders) will provide the data input into the dedicated online questionnaire.
Study Population 130 Patients who were treated with mepolizumab in six severe-asthma clinics in Poland between December 2017 and December 2019 . In the drug program in Poland it was mandatory to conduct the control examinations at the 24th and 52nd week of the treatment . In the proposed study we will use this information to evaluate study endpoints. Only patients who have been treated for at least 52 weeks are included into the study
Variables concerning the primary endpoints
- Asthma exacerbations measured at qualification for the treatment (in the period of previous 52 weeks) and at the 24th and 52nd week of the treatment.
- Oral Corticosteroids use dose (documented at qualification for the treatment and at the 24th and 52nd week of the treatment)
Variables concerning the secondary endpoints:
- ACQ-5 score (measured at qualification for the treatment and every 4 weeks thereafter)
- AQLQ score (measured at qualification for the treatment and every 4 weeks thereafter)
- Pre-bronchodilator FEV1 (measured at qualification for the treatment and every 4 weeks thereafter)
- Blood eosinophil counts (measured at qualification for the treatment and at the 24th and 52nd week of the treatment)
연구 유형
등록 (예상)
연락처 및 위치
연구 연락처
- 이름: Marcin Kurowski, MD, PhD
- 전화번호: +48601365911
- 이메일: marcin.kurowski@umed.lodz.pl
연구 연락처 백업
- 이름: Aleksandra Wardzyńska, MD, PhD
- 전화번호: +48693652775
- 이메일: aleksandra.wardzynska@umed.lodz.pl
연구 장소
-
-
-
Lodz, 폴란드, 92-213
- Medical University of Lodz, Dept. of Immunology and Allergy
-
연락하다:
- Marcin Kurowski, MD, PhD
- 전화번호: +48601365911
- 이메일: marcin.kurowski@umed.lodz.pl
-
연락하다:
- Aleksandra Wardzyńska, MD, PhD
- 전화번호: +48693652775
- 이메일: aleksandra.wardzynska@umed.lodz.pl
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
* The availability of the complete data
- Duration of treatment with mepolizumab: ≥ 52 weeks
- Satisfying the Polish drug programme inclusion criteria:
- Age >18
Before treatment with mepolizumab (BSAT inclusion criteria):
- High doses of ICS + one other controlling medication (i.e. LABA)
- ≥2 exacerbations in the previous year
- ≥350 eosinophil cells/μl in the blood at the time of qualifying, or in the previous year
- Pre-bronchodilator FEV1 < 80%
Exclusion Criteria:
* Duration of treatment with mepolizumab < 52 weeks
• Lack of complete data
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
---|---|
Severe asthma patients treated with mepolizumab
Patients having received mepolizumab 100 mg SC every 4 weeks for at least 12 months in six severe-asthma clinics in Poland between December 2017 and December 2019
|
Mepolizumab administered within the frame of a severe asthma treatment program financed by National Health Fund in Poland for patients fulfilling specific criteria of asthma severity.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Asthma exacerbations measured at qualification for the treatment (in the period of previous 52 weeks) and at the 24th and 52nd week of the treatment
기간: 5 months from the study beginning
|
Data as transferred from the treatment program questionnaires to the Study Data Sheet.
Asthma exacerbations, defined according to the Polish drug programme, is the worsening in asthma requiring (1) use of systemic corticosteroids or (2) increase in dose of OCS for more than 3 days in case of patients who are chronically treated with OCS.
|
5 months from the study beginning
|
Oral Corticosteroids use dose (documented at qualification for the treatment and at the 24th and 52nd week of the treatment)
기간: 5 months from the study beginning
|
Data as transferred from the treatment program questionnaires to the Study Data Sheet
|
5 months from the study beginning
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
ACQ-5 score (measured at qualification for the treatment and every 4 weeks thereafter)
기간: 5 months from the study beginning
|
Data as transferred from the treatment program questionnaires to the Study Data Sheet
|
5 months from the study beginning
|
AQLQ score (measured at qualification for the treatment and every 4 weeks thereafter)
기간: 5 months from the study beginning
|
Data as transferred from the treatment program questionnaires to the Study Data Sheet
|
5 months from the study beginning
|
Pre-bronchodilator FEV1 (measured at qualification for the treatment and every 4 weeks thereafter)
기간: 5 months from the study beginning
|
Data as transferred from the treatment program questionnaires to the Study Data Sheet
|
5 months from the study beginning
|
Blood eosinophil counts (measured at qualification for the treatment and at the 24th and 52nd week of the treatment)
기간: 5 months from the study beginning
|
Data as transferred from the treatment program questionnaires to the Study Data Sheet
|
5 months from the study beginning
|
공동 작업자 및 조사자
협력자
수사관
- 수석 연구원: Marcin Kurowski, MD, PhD, Medical University of Lodz
연구 기록 날짜
연구 주요 날짜
연구 시작 (예상)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .